In yesterday’s Wall Street session, Vera Therapeutics Inc (NASDAQ:VERA) shares traded at $42.19, up 0.21% from the previous session.
VERA stock price is now -7.21% away from the 50-day moving average and 3.62% away from the 200-day moving average. The market capitalization of the company currently stands at $2.67B.
With the price target of $70, Wells Fargo recently initiated with Overweight rating for Vera Therapeutics Inc (NASDAQ: VERA). , while ‘Oppenheimer’ rates the stock as ‘Outperform’
In other news, MARSHALL FORDYCE, Director bought 17,500 shares of the company’s stock on Jan 08 ’25. The stock was bought for $736,750 at an average price of $42.10. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 18 ’24, PRESIDENT AND CEO Fordyce Marshall sold 17,500 shares of the business’s stock. A total of $753,680 was realized by selling the stock at an average price of $43.07. This leaves the insider owning 85,942 shares of the company worth $3.63 million. A total of 22.63% of the company’s stock is owned by insiders.
During the past 12 months, Vera Therapeutics Inc has had a low of $14.20 and a high of $51.61. As of last week, the company has a debt-to-equity ratio of 0.19, a current ratio of 13.60, and a quick ratio of 13.60. The fifty day moving average price for VERA is $45.446 and a two-hundred day moving average price translates $40.709 for the stock.
The latest earnings results from Vera Therapeutics Inc (NASDAQ: VERA) was released for 2024-09-30. The company reported revenue of $49.8 million for the quarter, compared to $21.76 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 128.91 percent.
